Gene therapy using Fas ligand (FasL) for treatment of tumours and protection of transplant rejection is hampered because of the systemic toxicity of FasL. In the present study, recombinant replication-defective adenovirus vectors (RAds) encoding FasL under the control of either the neuronal-specific neuronal-specific enolase (NSE) promoter or the astrocyte-specific glial fibrillary acidic protein (GFAP) promoter have been constructed. The cell type-specific expression of FasL in both neurons and glial cells in primary cultures, and in neuronal and glial cell lines is demonstrated. Furthermore, transgene expression driven by the neuronal and glial promoter was not detected in fibroblastic or epithelial cell lines. Expression of FasL driven by a major immediate early human cytomegalovirus promoter (MIEhCMV) was, however, achieved in all cells tested. As a final test of the stringency of transgene-specific expression, the RAds were injected directly into the bloodstream of mice. The RAds encoding FasL under the control of the non-cell type-specific MIEhCMV promoter induced acute generalized liver haemorrhage with hepatocyte apoptosis, while the RAds containing the NSE or GFAP promoter sequences were completely non-toxic. This demonstrates the specificity of transgene expression, enhanced safety during systemic administration, and tightly regulated control of transgene expression of highly cytotoxic gene products, encoded within transcriptionally targeted RAds.
Introduction
Fas ligand (FasL) induces apoptosis in cells expressing the apoptosis receptor, Apo1\Fas (CD95) (Suda & Nagata, 1994 ; Suda et al., 1993) . The main function of FasL and Apo1\Fas is the maintenance of immune homeostasis (through induction of activation-dependent cell death) (Osborne, 1996 ; van , 1996) . FasL is also thought to contribute to the maintenance of the immune-privileged status of organs such as the brain, the anterior chamber of the eye and the testis (Bellgrau et al., 1995 ; Griffith et al., 1996 ; Griffith & Ferguson, 1997 ; Saas et al., 1997) . Importantly, however, FasL can also act as a pro-inflammatory cytokine, attracting the infiltration of granulocytes (Allison et al., 1997 ; Green & Ware, 1997) . Thus, FasL or FasL-expressing cells have been used to prevent allogeneic transplant rejection (Korbutt et al., 1997 ; Lau et al., 1996 ; Sanberg et al., 1996) ; however, whether or not the sole expression of FasL can provide complete protection from immune rejection remains contested (Kang et al., 1997 ; Zhang et al., 1997) . To what extent the function of FasL is influenced by its level and timing of expression, the particular cell type expressing FasL, its associated pro-inflammatory role, or the individual experimental models being examined, remains to be determined (Griffith & Ferguson, 1997 ; Vaux, 1995) .
Recombinant replication-defective adenovirus vectors (RAds) are well suited for gene transfer into post-mitotic nondividing cells, such as neurons (Hashimoto et al., 1996 ; Shering et al., 1997) . In addition, they have been shown to be useful in achieving cell type-specific expression of marker transgenes in a variety of tissues, such as brain (Hashimoto et al., 1996 ; Shering et al., 1997) and other tissues (Hoffman et al., 1997 ; Imler et al., 1996 ; Kanai et al., 1996 ; Kim et al., 1997 ; Ko et al., 1996 ; Lan et al., 1997 ; Morishita et al., 1995 ; Rodriguez et al., 1997 ; Rothmann et al., 1996 ; Sandig et al., 1996 ; Siders et al., 1996) .
However, RAds induce an immune response when injected into the brain (Byrnes et al., 1996 ; Kajiwara et al., 1997) . Nevertheless, Geddes et al. (1997) have demonstrated longterm transgene expression. Furthermore, immune-suppression extends transgene expression in the liver (Kay et al., 1997) and the brain (Geddes et al., 1996) . Thus, strategies to prolong transgene expression from RAds in the brain are needed because many diseases to be treated will necessitate very longterm therapeutic transgene expression and\or readministration of therapeutic vectors. Interestingly, several tumours (Hahne et al., 1996 ; Niehans et al., 1997 ; O'Connell et al., 1996) , including brain gliomas (Saas et al., 1997 ; Wrann et al., 1987) , have been recently shown to express FasL in addition to TGF-β, thought to contribute to the immune-suppressive capacity of the tumours. Interestingly, these cytokines may also be of use in prolonging RAd-mediated transgene expression in the brain, as has been attempted for other organs (Sata et al., 1998 ; Zhang et al., 1998) .
The challenge of using FasL to treat Apo1\Fas-positive tumours (Seino et al., 1997 ; Shimizu et al., 1996 ; Weller et al., 1994 ; Zhang et al., 1998) or to prevent rejection of organ allografts is complicated by the fact that activation of Apo1\Fas induces liver failure and apoptosis of hepatocytes (Ogasawara et al., 1993 ; Rensing-Ehl et al., 1995) . To restrict the expression of FasL and thus avoid systemic toxicity, we assessed whether neuronal promoters could be used to limit expression of FasL to either neurons or glial cells. We demonstrate that the expression of FasL can indeed be restricted to predetermined cell types by transcriptional targeting of RAds, thereby greatly reducing and\or eliminating possible systemic liver toxicity.
Methods
Cell lines and primary cultures. The murine neuroblastoma cell line Neuro-2a, the rat glial tumour cell line C6, the mouse rectal carcinoma cell line CMT93\69 and the hamster fibroblast kidney cell line BHK 21 CL13(IZS) were purchased from the European Collection of Animal Cell Cultures (Porton Down, Salisbury, UK). The rat glioblastoma cell line CNS-1 was kindly provided by William Hickey (Pathology Dept, Dartmouth Medical School, New Hampshire, USA) ; the rat glioblastoma cell line 9L was kindly provided by Walter Risau (Bad Nauheim, Germany) ; and the murine lymphoma cell line Yac-1 was obtained from the ATCC. All cell lines were grown in Dulbecco's modified Eagle medium supplemented with 10 % foetal calf serum (FCS), 2 mM glutamine, 100 mM non-essential amino acids, 100 U\ml penicillin and 100 mg\ml streptomycin sulphate (Gibco). Kidney embryonic 293 cells (originally from Microbix Biosystems) expressing low levels of Apo1\ Fas (Larregina et al., 1998) were cultured as described by Shering et al. (1997) . Neuronal and glial cultures were prepared as previously described (Lowenstein et al., 1994 (Lowenstein et al., , 1995 Shering et al., 1997) .
Reagents and primary antibodies. Recombinant soluble human Fas lacking the transmembrane domain (FasTM) was purchased from PharMingen. Forskolin, Triton X-100, propidium iodide, RNase A, BSA and mouse monoclonal antibodies specific for vimentin (clone V9) and for MAP-2 (clone HM-2) were purchased from Sigma. The monoclonal antibody anti-glial fibrillary acidic protein (GFAP ; clone G-A-5) was obtained from Boehringer Mannheim. The rabbit polyclonal serum recognizing neuronal-specific enolase (NSE) was obtained from Dako (code L1830). The rabbit polyclonal antibody C-178, recognizing amino acids 100-278 mapping at the carboxyl terminus of rat FasL and crossreacting with FasL of mouse and human origin was obtained from Santa Cruz Biotechnology.
Construction of RAd-CMV-FasL, RAd-NSE-FasL and RAd-GFAP-FasL. The 880 bp murine FasL cDNA fragment was subcloned from the BCMGS Neo expression plasmid into the BamHI site of the pAL119 shuttle vector. The pAL119 vector contains the truncated major immediate early human cytomegalovirus (MIEhCMV) promoter (k299 to j69) and the simian virus 40 (SV40) poly(A) signal and is described in Shering et al. (1997) and in Wilkinson & Akrigg (1991) . A 3071 bp fragment containing the 1800 bp rat NSE promoter (described in ForssPeter et al., 1990) , the murine FasL cDNA (880 bp), and the SV40 poly(A) (300 bp) were subcloned into the XhoI sites of the pAL119 shuttle vector. A 2571 bp fragment containing the murine GFAP promoter (described by Miura et al., 1990) , the murine FasL cDNA and the SV40 poly(A) were inserted into the XhoI sites of the pAL119 shuttle vector. RAds were generated by co-transfection of 293 cells using the calcium phosphate precipitation method with each recombinant pAL119 shuttle vector together with pJM17. The plasmid pJM17 comprises a circular and unpackageable form of the adenovirus type 5 genome, with deletions in E1 and E3 (Microbix Biosystems). Before and after three rounds of virus purification by end-point dilution, the viral DNA was checked by HindIII digestion followed by Southern blot hybridization (Fig. 1) . RAds containing appropriate transgenic constructs were scaled up and purified by two caesium chloride gradients. Virus titre was measured by standard end-point dilution assay using 293 cells. As a control, we used a RAd encoding the E. coli β-galactosidase gene under the control of the MIEhCMV promoter (RAd-MIEhCMV-lacZ) (described as RAd35 in Shering et al., 1997) .
Flow cytometric analysis of primary cultures and cell lines.
Flow cytometric analysis is described in detail by Castro et al. (1997) . The primary antibodies used were mouse monoclonal antibodies specific for MAP-2 or GFAP, and rabbit polyclonal sera recognizing NSE, FasL or vimentin. The secondary antibodies were fluorescein (FITC)-conjugated donkey anti-mouse IgG, or FITC-conjugated swine anti-rabbit Igs. As irrelevant controls, the same cells were incubated with irrelevant mouse IgG1 or with normal rabbit serum instead of primary antibodies.
Detection of apoptosis by flow cytometry. Cells were fixed with 4 % paraformaldehyde, permeabilized with 0n1 % Triton X-100 in PBS, and incubated with propidium iodide to stain DNA, as was previously described by Nicoletti et al. (1991) . Following permeabilization, propidium iodide incorporates into DNA, and apoptotic cells display a broad hypoploid DNA peak, clearly separated from the normal diploid distribution of DNA within non-apoptotic cells. The fluorescence intensity of 5i10% cells was analysed using a FACScan (Becton Dickinson).
Simultaneous detection of MAP-2 or GFAP and apoptosis in cells from primary cultures was performed by flow cytometry. Briefly, cells were : (i) fixed with 4 % paraformaldehyde in PBS, pH 7n4, for 15 min at 4 mC ; (ii) permeabilized with 0n1 % Triton X-100, 150 mM NaCl, 1 mM HEPES, 4 % FCS in PBS, for 10 min at 4 mC ; (iii) incubated with the optimal dilution of the primary monoclonal antibody (anti-MAP-2 or anti-GFAP) in PBS containing 200 mg\ml RNase A, 10 mg\ml propidium iodide and 1 % BSA for 1 h at 4 mC ; and (iv) incubated with FITCconjugated donkey anti-mouse IgG (Jackson Immunoresearch Laboratories). The fluorescence intensity of 5i10% cells was analysed by flow cytometry using a FACScan. Analysis of the DNA content in the subpopulations of MAP-2-positive or GFAP-positive cells determined the percentage of apoptotic neurons and astrocytes, respectively, in primary cultures.
Systemic administration of RAd. Eight 6-10-week-old BALB\c (H-2 d ) female mice were infused via the tail vein with 2i10* or 2i10"! p.f.u. RAd-MIEhCMV-FasL, RAd-NSE-FasL, RAd-GFAPFasL or RAd-MIEhCMV-lacZ. Animals were sacrificed at 6 h, and the livers were dissected for histopathology.
Statistical analysis. ANOVA and ad hoc Student, Newman Kules and Dunnet were used to compare percentages of apoptosis induced by cell supernatants. A comparison between media from cells infected at two different m.o.i.s was analysed by the two-tailed Student t-test.
Results

Neuronal and glial cell lines infected with RAd-NSE-FasL and RAd-GFAP-FasL induce FasL and Apo1/Fas-dependent cytotoxicity
To demonstrate that active FasL can be expressed under the control of tissue-specific promoters, Neuro-2a cells, a neuroblastoma cell line, and CNS-1 cells, a glioblastoma cell line, were infected with different m.o.i.s of either RAd-NSE-FasL or RAd-GFAP-FasL, respectively. The construction of RAd-NSE-FasL, RAd-GFAP-FasL and RAd-MIEhCMV-FasL is described in Methods and in Fig. 1 . Neuro-2a cells were chosen as targets of infection with RAd-NSE-FasL because they express NSE and lack Apo1\Fas (Rensing-Ehl et al., 1996) . CNS-1 cells were selected to be infected with RAd-GFAPFasL because they are positive for GFAP and showed low sensitivity to FasL-mediated cytotoxicity (A. Fontana, unpublished results). After infection with RAds, subconfluent cultures were maintained at low serum concentration (1 %) for 48-72 h. At that time, culture supernatants were collected, filtered and incubated with Yac-1 lymphoma cells for 18 h, after which the percentage of apoptotic Yac-1 cells was assessed by flow cytometry. Yac-1 cells were selected as targets for the apoptosis assays because they express Apo1\Fas and are known to be sensitive to FasL-induced cytotoxicity (Rensing-Ehl et al., 1995) . Supernatant from approximately 5i10& infected cells was incubated with (Fig.  2 A) . The cytotoxic effect was not related to adenovirus infection of Neuro-2a cells per se, since the supernatant of Neuro-2a cells infected with the same m.o.i.s of the control virus RAd-MIEhCMV-lacZ did not induce apoptosis of Yac-1 cells. To demonstrate that the cytotoxic effect was due to the presence of soluble FasL (sFasL) in the supernatant of Neuro-2a cells infected with RAd-NSE-FasL (m.o.i. l 1000), twofold dilutions of culture supernatant were incubated with Yac-1 in the presence or absence of 500 ng\ml soluble human Apo1\ Fas (sFas). sFas would be expected to block specifically FasLinduced cell death by sequestering sFasL from the supernatant or competing with the binding of sFasL to Apo1\Fas on Yac-1 cells. Indeed, the cytotoxic effect of supernatant from RAd-NSE-FasL-infected Neuro-2a cells (Fig. 2 B) was significantly blocked by sFas at a concentration of 500 ng\ml. To further support the hypothesis that the cytotoxic effect was due to the presence of sFasL in the supernatant and not due to unrelated non-specific factors, the supernatant of Neuro-2a cells infected with RAd-NSE-FasL (m.o.i. l 1000) was incubated with target 9L cells, which do not express Apo1\Fas (not shown). Supernatant obtained from Neuro-2a cells infected with RAd-MIEhCMV-FasL (m.o.i. l 1000) was not cytotoxic to 9L cells.
The supernatant of CNS-1 cells infected with different m.o.i.s of RAd-GFAP-FasL also induced apoptosis in Yac-1 cells (Fig. 2 C) . The cytotoxic effect was blocked by sFas (Fig.  2 D) and the supernatant was not cytotoxic to 9L cells (not shown), demonstrating that CNS-1 cells infected with RAd-GFAP-FasL are able to release sFasL into the culture medium.
Cell type-specific expression and secretion of sFasL in neuronal and glial primary cultures infected with RAds
Rat neocortical neuronal primary cultures and rat glial primary cultures were infected with RAd-NSE-FasL and RAd-GFAP-FasL to determine whether the FasL expression was restricted to separate brain cell subpopulations when the transgene was under the control of brain cell type-specific promoters. Three-day-old neuronal primary cultures were infected with increasing m.o.i.s of RAd-NSE-FasL and RAd-GFAP-FasL and maintained at low serum medium (1 %) for a further 3 days. At that time the supernatant was harvested, filtered and incubated with Yac-1 cells for 18 h. As a positive control we infected cells with RAd-MIEhCMV-FasL (at a single m.o.i. l 500). RAd-MIEhCMV-lacZ was used as an irrelevant control. Primary cultures were characterized by immunostaining and flow cytometric analysis. We determined that rat neocortical neurons in primary culture at the time of infection were composed of 90 % of MAP-2-and NSE-positive cells (neurons), and 6 % of GFAP-positive cells (astrocytes) (data not shown).
Neurons infected with increasing input of RAd-NSE-FasL, and to a lesser extent the positive control, RAdMIEhCMV-FasL, released cytotoxic FasL into the culture supernatants (Fig. 3 A) . The lower effect induced by RAdMIEhCMV-FasL compared to RAd-NSE-FasL is expected, since we have previously shown that the activity of the truncated MIEhCMV promoter is very low in neurons (Shering et al., 1997) . On the other hand, RAd-GFAP-FasL and the control virus, RAd-MIEhCMV-lacZ, did not show any increase in the cytotoxic activity of the supernatant (Fig. 3 A) . However, we were not able to detect FasL expression by flow cytometry on the cell surface of neurons either in control conditions (without infection or infected with RAdMIEhCMV-lacZ ; Fig. 3 B) or after infection with RAd-NSE-FasL (m.o.i. l 1000 ; Fig. 3 C) . Thus, FasL must be mainly secreted by neurons into the supernatant (neurons are secretory cells), released from the cellular membrane by proteolysis, or released by shedding from the plasma membrane (Schneider et al., 1998) . This agrees with results obtained with the neuronal cell line Neuro-2a cells stably transfected with mouse FasL cDNA : FasL detected in the supernatant of transfected cells comprised the membrane FasL rather than sFasL, the latter being only weakly active on target cells (Schneider et al., 1998) .
To determine the expression of FasL under the control of tissue-specific promoters in astrocytes, 1-week-old primary glial cultures were infected with the same set of RAds. As expected, RAd-GFAP-FasL and the positive control, RAdMIEhCMV-FasL, induced cytotoxic activity in the culture supernatant (Fig. 3 D) . Interestingly, RAd-NSE-FasL also induced cytotoxic activity in the supernatant of glial cultures. These results are not unexpected, since, using immunostaining and flow cytometric analysis, we determined that in the population of glial cells in primary cultures at the time of infection 75 % of cells expressed GFAP (expressed in astrocytes), 96 % of cells were positive for vimentin (expressed in astrocytes, astrocyte precursors, endothelial cells and fibroblasts) and less than 2 % of cells expressed MAP-2 (a neuronalspecific protein). Interestingly, 90 % of cells were positive for NSE (a protein expressed by activated astrocyte precursors in active division). Thus, most GFAP-positive cells also expressed NSE, explaining why both promoters within adenovirus could drive expression of FasL in our glial cultures. Unlike neurons, cell surface expression of FasL in astrocytes could be detected after infection with RAd encoding FasL (Fig. 3 E, F) , suggesting that the dynamics of subcellular expression and secretion of FasL may differ in neurons and astroyctes.
Differential sensitivity of neurons and astrocytes to apoptosis induced by FasL
Three-day-old neocortical primary cultures were infected with increasing m.o.i.s of RAd-NSE-FasL, RAd-GFAP-FasL, RAd-MIEhCMV-FasL or the control virus, RAdMIEhCMV-lacZ. Three days after infection, cells were harvested, stained for apoptosis, immunolabelled for MAP-2 and analysed by flow cytometry. Using this approach, we determined, by electronic gating of MAP-2-positive cells, the percentage of apoptotic neurons at different m.o.i.s with each RAd. The percentage of apoptotic neurons in primary cultures infected with RAd-NSE-FasL or RAd-MIEhCMV-FasL (two vectors which do induce the secretion of sFasL in neurons) was similar (P 0n5) to cultures infected with RAd-GFAP-FasL or RAd-MIEhCMV-lacZ (two vectors which do not induce the secretion of sFasL in neurons) (Fig. 4 A) . However, there was a significant increase (P l 0n0001) in neuronal cell death for all RAds tested, when RAds were used at an m.o.i. of 500 or 1000, similar to what we reported earlier (Shering et al., 1997) .
On the contrary, GFAP-positive cells in primary cultures were susceptible to the cytotoxic effects of Apo1\Fas-mediated cytotoxicity produced by all three RAds expressing FasL (Fig. 4 B) . Significantly more astrocytes died by apoptosis following a 3 day infection with RAd-GFAP-FasL, RAd-NSE-FasL and RAd-MIEhCMV-FasL at an m.o.i. of 500 or 1000 (P 0n0001) compared to lower m.o.i.s. RAdMIEhCMV-lacZ did not induce an increase in astrocyte apoptosis even at the higher m.o.i.s, indicating that RAd infection per se is not cytotoxic to astrocytes.
Differential expression of FasL under NSE and GFAP promoters in neuronal, glial fibroblastic, epithelial and fibroblastic cell lines
We further examined the cell type specificity of RAd-NSE-FasL and RAd-GFAP-FasL expression using two different neuronal cells lines (Neuro-2a and GN11), three glioblastoma cells lines (CNS-1, 9L and C6), a colonic epithelial cell line (CMT93\69) and a fibroblast cell line (BHK). Each cell line was infected with increasing m.o.i.s of RAd-NSE-FasL, RAd-GFAP-FasL and RAd-MIEhCMV-lacZ, as an irrelevant control. RAd-MIEhCMV-FasL was only used at an m.o.i. of 500 as a positive control in our assay, given the non-cell typespecific activity of the truncated MIEhCMV promoter. In all experiments 48-72 h post-infection, the supernatant was harvested, filtered, incubated with Yac-1 cells for 18 h, and the percentage of apoptotic cells was analysed by flow cytometry. At the same time the expression of intracellular NSE and GFAP proteins was assessed in each cell line by immunostaining followed by flow cytometry (Fig. 5) .
RAd-NSE-FasL induced the expression of FasL in both neuronal cell lines (both expressing immunoreactive NSE protein). Interestingly, in spite of the lack of detectable expression of GFAP protein in Neuro-2a cells, infection with RAd-GFAP-FasL at m.o.i.s higher than 500 led to FasL secretion into the supernatant. GN11 cells expressed GFAP immunoreactivity and also allowed FasL production following infection with RAd-GFAP-FasL. Infection of the CNS-1 and 9L glioblastoma cell lines, which express GFAP protein, with RAd-GFAP-FasL induced the release of sFasL. Interestingly, in the C6 cell line, RAd-GFAP-FasL only released sFasL after cells were induced to up-regulate the expression of GFAP protein during differentiation induced by 3 days of incubation with forskolin (50 µM). In accordance with the intracytoplasmic detection of NSE protein, RAd-NSE-FasL induced the release of sFasL, following infection of all glial cell lines. However, even if undifferentiated C6 cells expressed high levels of NSE protein, expression from RAd-NSE-FasL only became detectable after cells were induced to differentiate. We did not find cytotoxic activity in supernatants harvested from CMT69 and BHK cell lines after infection with either RAd-NSE-FasL or RAd-GFAP-FasL.
RAd-NSE-FasL and RAd-GFAP-FasL do not induce hepatic cytotoxicity after systemic administration
The liver is very susceptible to FasL-mediated cytotoxicity (Galle et al., 1995) . To determine the selectivity of adenovirally encoded FasL expression under the control of the cell typespecific promoters NSE and GFAP in peripheral tissues in vivo, we injected mice, via the tail vein, with two different doses of RAd-NSE-FasL and RAd-GFAP-FasL. As controls, RAdMIEhCMV-FasL and RAd-MIEhCMV-lacZ were included. Mice injected with 2i10* or 2i10"! p.f.u. RAdMIEhCMV-FasL revealed massive hepatic apoptosis and haemorrhage within 6 h after injection. No macroscopically detectable injury of spleen, intestinal tract, brain, kidney, lung and heart were detected. Microscopically, hepatocytes displayed fragmented and condensed nuclei indicative of apoptosis. Hepatic sinusoids were dilated with loss of the endothelial lining, and severe haemorrhage was present throughout the liver (Fig. 6 B) . In contrast, mice injected with the same doses of RAd-NSE-FasL, RAd-GFAP-FasL or the control vector, RAd-MIEhCMV-lacZ, were clinically healthy and the hepatic tissue was histologically normal (Fig. 6 A, C, D) .
Discussion
FasL induces apoptosis through the cross-linking of its receptor, Apo1\Fas (Suda & Negata, 1994 ; Suda et al., 1993) . FasL is a transmembrane protein, which can also be released into the medium through proteolytic cleavage or shedding from the plasma membrane (Kayagaki et al., 1995) . Recombinant adenoviruses expressing FasL under the control of viral or cell type-specific promoters were constructed and used to infect cells of neuronal, glial, epithelial and fibroblastic lineage. All cell lines released sFasL into the culture medium when infected with RAd-MIEhCMV-FasL.
Infection of neuroblastoma Neuro-2a cells with RAd-NSE-FasL, and glioma CNS-1 cells with RAd-GFAP-FasL demonstrated that cells of neuronal and glial lineage were able to activate the appropriate cell type-specific promoters. We confirmed that the cytotoxic activity released following infection was indeed due to FasL, through its inhibition with sFas and the selective induction of apoptosis in 9L glioma cells stably transfected with Apo1\Fas, but not in cells not expressing the FasL receptor.
Infection of neurons grown in primary cultures released higher levels of sFasL when infected with RAd-NSE-FasL, compared to infection with RAd-MIEhCMV-FasL. This confirms previous data from our laboratory which indicated that the truncated MIEhCMV promoter (k299 to j69) does not lead to high level transgene expression in neocortical neurons in primary cultures (Shering et al., 1997) . Infection with RAd-GFAP-FasL did not induce expression of FasL in neurons, even at an m.o.i. of 1000, demonstrating tight cell type-specific expression from this promoter in neurons in primary culture. This demonstrates cell type-restricted expression of adenovirus-encoded transgenes in neurons in primary culture, when transcription is directed from neuronal and glial promoters.
No FasL was detected on the membrane of neurons by flow cytometry, suggesting that most of the transgenic FasL is being released rapidly into the medium. Further, very low basal levels of supernatant cytotoxicity in the presence of infection with RAd-MIEhCMV-lacZ was detected. Taken together, this suggests that either no, very low level or inactive FasL is expressed endogenously by neocortical neurons. So far, only one report showed expression of FasL by immunocytochemistry in rat embryonic brain and spinal cord neurons (French et al., 1996) , while another demonstrated the presence of FasL protein in neurons (Saas et al., 1997) .
Infection of glial cells grown in primary culture, however, demonstrated low activity of both the GFAP and NSE promoters, while high level expression of FasL was obtained upon infection with RAd-MIEhCMV-FasL. Glial cells released transgenic sFasL into the medium, and also expressed detectable FasL on their plasma membrane. FasL expression was only detected following infection with recombinant viruses encoding FasL, but not in their absence.
Infection of glial cells with RAds containing either the GFAP or NSE promoter achieved a comparable release of sFasL, measured as Yac-1 apoptosis. In adult transgenic mice, the GFAP (Brenner et al., 1994) and NSE (Forss-Peter et al., 1990) promoters direct, respectively, specific astrocyte and neuronal transgene expression in the brain. Thus, it is very likely that the activated status of astrocytes in primary culture leads to the expression of the NSE promoter from RAds in glia. Indeed, immunostaining demonstrated that glial cells in culture expressed high levels of NSE, as do glial cells during gliosis in vivo (Lin & Matesic, 1994) It is thus interesting to compare the lack of expression of FasL by neuronal and glial cells in primary culture, to brain gliomas which express significant amounts of FasL. FasL expressed by tumour cells could play a role in the downmodulation of anti-tumour immunity through apoptosis of infiltrating cytotoxic T lymphocytes (Strand et al., 1996) . RAds encoding FasL induced astrocyte apoptosis. This confirms that astrocytes, unlike oligodendrocytes in culture, express functional Apo1\Fas (Malipiero et al., 1997) . In neurons, however, these same RAds did not induce FasLmediated neuronal apoptosis. Neurons express only low levels of Apo1\Fas and are resistant to FasL-mediated killing even when pretreated with cytokines (Rensing-Ehl et al., 1996) . Nevertheless, neurons were sensitive to a non-specific neurotoxic effect of RAd infection. Whether neuronal apoptosis is due to direct virus cytotoxicity, or secondary to the release of pro-inflammatory and cytotoxic cytokines or mediators remains to be determined.
Thus, in vivo our vectors could be cytotoxic to certain (i.e. reactive) glial subpopulations. If inflammation-induced glial activation in vivo induces up-regulation of Apo1\Fas, they would become sensitive to FasL-induced apoptosis (Nishimura et al., 1995) . Thus, expression of FasL by astrocyte-derived tumours, could induce apoptosis of reactive peri-tumoural glial cells (Saas et al., 1997) . Further, since antigen-presenting dendritic cells, macrophages and brain microglia are all sensitive to FasL-induced apoptosis, FasL also might allow the long-term expression from RAd injected into the brain (Bonetti et al., 1997 ; Kiener et al., 1997 ; Koppi et al., 1997) . Furthermore, adenovirus-encoded anti-apoptotic gene products within the E1 and E3 regions (Boyd et al., 1994 ; Tollefson et al., 1998) are all absent from our recombinant vectors.
FasL was not expressed in either epithelial or fibroblastic cell lines infected with RAd-NSE-FasL or RAd-GFAP-FasL (even at m.o.i. of 1000). This conclusively demonstrates that in cell lines of non-neuronal lineage, the neuronal and glial promoters do remain completely silent. In cells of neuronal lineage, however, the results were more complex.
In general, we detected a correlation between endogenous expression of NSE and GFAP, and expression from the respective promoters within RAd. The correlation, however, was not perfect. Thus, in GFAP-negative Neuro-2a cells at high, but not low m.o.i.s, both the NSE and GFAP promoters were active. This could indicate differences in the regulation of the endogenous GFAP promoter compared to GFAP promoter sequences encoded within RAd. Cell type-specific, m.o.i.-dependent expression in neuronal cells was described by us earlier (Shering et al., 1997) .
The GN11 neuronal cell line (NSE-and GFAP-positive) expressed FasL from both the NSE and GFAP promoters. Expression from both promoters was also obtained following infection of the glioma CNS-1 and 9L cells. Expression of FasL in undifferentiated glioma C6 cells infected with RAd-NSE-FasL was very low ; forskolin differentiation, however, increased endogenous GFAP expression, and allowed expression after infection with RAd-GFAP-FasL. Expression following infection with RAd-MIEhCMV-FasL was not modified by forskolin treatment.
Interestingly, levels of expression from RAds did not parallel the endogenous level of NSE or GFAP protein in neuronal cells. Differences in the sequences or methylation status of the endogenous versus the virally encoded promoter could account for the differences observed. That promoters encoded within RAd effectively restrict expression to cells of the predictive lineage is most clearly demonstrated with the epithelial and fibroblastic cell lines, which even when infected at m.o.i.s of 1000 did not activate the GFAP or the NSE promoters.
Hashimoto et al. (1996) examined the cell type-specificity of either the Purkinje neuron-specific (L7) promoter or the oligodendrocyte-specific (myelin basic protein) promoter within RAds. They demonstrated cell type-specific transgene expression in vitro, but only studied a single m.o.i. of 100. In vivo, they detected expression in Purkinje cells and oligodendrocytes. However, strong expression of the transgene made it difficult to identify all transduced cell types, and to carry out a thorough assessment of possible promoter leakiness. Peel et al. (1997) using adeno-associated virus vectors, also demonstrated restricted neuronal-specific expression from the NSE and the platelet-derived growth factor promoter in spinal cord neurons in vivo.
Importantly, BHK cells infected with a recombinant replication-deficient herpes simplex virus type 1 (HSV-1) expressing luciferase under the control of the NSE promoter did express the transgene (Roemer et al., 1995) . BHK cells, however, do not express NSE, and infection with RAd-NSE-FasL does not lead to transgene expression even at an m.o.i. of 1000. However, Andersen et al. (1992 Andersen et al. ( , 1993 and Kaplitt et al. (1994) have reported neuronal-specific expression in vitro and in vivo from a replication-defective recombinant or amplicon HSV-1 vectors by using the NSE or pre-proenkephalin promoter. It is thus likely that the virus vector into which a particular promoter is inserted can influence promoter activity (Shering et al., 1997) .
In support of this concept, we have previously shown that, in primary cultures of neocortical neurons, the truncated MIEhCMV promoter did not allow detectable neuronal transgene expression from a RAd, unless activated by superinfection with HSV-1, MIEhCMV or wild-type adenovirus (Shering et al., 1997) . Transgene expression from HSV-1 vectors deleted in all HSV-1 immediate early functions (Samaniego et al., 1997 (Samaniego et al., , 1998 demonstrates that expression from the MIEhCMV promoter is very low unless the HSV-1 immediate early protein ICP0 is present. Thus, vector-encoded transactivators can influence expression from a transgenic promoter located within recombinant virus vectors. Thus, our data show that RAds are a potent expression system that allows cell type-specific transgene expression in post-mitotic cells, such as neurons.
As a stringent test of the cell type-specific expression of our promoters, all viruses were administered, systemically, to the liver of mice, which is exquisitely sensitive to FasL-induced cytotoxicity (Galle et al., 1995 ; Muruve et al., 1997) . Only RAd-MIEhCMV-FasL induced generalized liver apoptosis and haemorrhage. This experiment demonstrates that no significant expression was obtained from either the GFAP or NSE promoter in the liver in vivo, and thus reinforces the robustness of transcriptional targeting of systemically administered RAds in vivo. Thus, our results support the development of transcriptional targeting of RAds to restrict expression of transgenes to predetermined cell types to reduce toxicity during the systemic administration of viruses for gene transfer\gene therapy applications.
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